PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference

FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune^® T-cell activating technology, today announced that the company’s Chief Medical Officer, Dr. Lauren V. Wood, will be presenting at the upcoming 2021 International Head and Neck Cancer Conference hosted by Cardiff, NHS Wales and The Swallows Head & Neck Cancer Support Group.

Dr. Lauren V. Wood will be joining Dr. Arthur M. Lauretano in hosting the 90-minute seminar titled “New Drugs in the Fight Against Head & Neck Cancer”. This seminar will focus on novel treatment approaches for head and neck cancer and working in collaboration with health professionals, patients, cancer survivors and drug companies in research, prevention, treatment, and care for those diagnosed with the disease. Dr. Wood will highlight the potential impact of the Company’s proprietary, Versamune^® T-cell activating technology on the treatment of HPV-associated head and neck cancer with PDS0101. 

The conference is taking place virtually from November 2 – 4, 2021. Details for the conference and seminar are as follows:

2021 International Head and Neck Cancer Conference:
Dates: November 2 – 4, 2021
Conference Link: https://www.trybooking.com/uk/events/landing?eid=17014&

Seminar: New Drugs in the Fight Against Head & Neck Cancer
Date: Wednesday November 3, 2021
Time: 9:15am UK (3:15 am ET)

Dr. Wood and Dr. Lauretano both bring a breadth of knowledge and experience to the table. Dr. Wood joined PDS Biotech as Chief Medical Officer in February 2019. She is responsible for clinical development of the novel, immune activating Versamune^® platform-based product pipeline that address a broad spectrum of solid tumors, including PDS Bio’s lead clinical candidate PDS0101 targeting HPV-related cancers. With 30 years of extensive clinical research experience at the National Institutes of Health, Dr. Wood most recently was the Clinical Director of the Vaccine Branch, Center for Cancer Research at the National Cancer Institute. While there, she oversaw the translational development of immune-based therapies for both cancer and HIV infection and was a co-inventor of two patented therapeutic cancer vaccine platforms targeting the TARP and HER tumor antigens.

Dr. Arthur Lauretano is an otolaryngologist currently serving as the Medical Director for the Lowell General Hospital Multidisciplinary Head and Neck Center and as the Chief Medical Officer at the Circle Health/Lowell General Hospital. Dr. Lauretano has his Master of Science in Healthcare Management and Clinical Informatics from the University of Massachusetts Lowell, and has a second board certification in Clinical Informatics from the American Board of Preventive Medicine. He is also a fellow of the American College of Surgeons. Dr. Lauretano also teaches at the Harvard Medical School and the Boston University School of Medicine. 

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune^® T-cell activating technology platform. Our Versamune^®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune^® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune^® based products and the Company’s or monitoring committees’ or other third parties’ interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment, significance of milestones, and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital